CASI Pharmaceuticals adds James Huang to board of directors

CASI Pharmaceuticals, Inc. (NASDAQ: CASI) announced the appointment of James Huang as an independent director to its board of directors, effective October 1, 2025.

Huang brings over 35 years of experience in biotechnology as an entrepreneur and investor. He serves as founder and managing partner of Panacea Venture and previously held the managing partner role at Kleiner Perkins China and Vivo Ventures. His earlier career included senior positions at Tularik Inc., GlaxoSmithKline LLC, Bristol-Myers Squibb and ALZA Corp.

Currently, Huang serves on the boards of Kindstar Globalgene Technology, Inc., Connect Biopharma Holdings Limited, Lee's Pharmaceutical Holdings Limited, Atara Biotherapeutics, Inc., and several private companies. He holds an MBA from Stanford Graduate School of Business and a bachelor's degree in chemical engineering from the University of California, Berkeley.

"I am honored to join the CASI Board as the company embarks on a pivotal new chapter with a sharpened U.S. focus and a commitment to rapidly advance clinical development of CID-103 in autoimmune diseases and antibody-mediated rejection in solid organ transplants," Huang said.

David Cory, CASI's chief executive officer, stated that Huang's global perspective and proven ability to scale companies will be valuable as the CID-103 anti-CD38 program progresses in clinical trials.

In connection with Huang's board appointment, Panacea Venture plans to acquire up to approximately 1.5 million newly issued shares of CASI common stock from the company in a registered transaction. Panacea Venture is currently a CASI shareholder.

CASI is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. The company is conducting a Phase 1/2 study in immune thrombocytopenic purpura and received FDA clearance for a Phase 1/2 study in renal allograft antibody-mediated rejection.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Gossamer Bio raises up to $250M in private placement for PAH drug
• reAlpha completes $8.5M InstaMortgage acquisition